|
1
|
Zhang R, Humphreys I, Sahu RP, Shi Y and
Srivastava SK: In vitro and in vivo induction of apoptosis by
capsaicin in pancreatic cancer cells is mediated through ROS
generation and mitochondrial death pathway. Apoptosis.
13:1465–1478. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stathis A and Moore MJ: Advanced
pancreatic carcinoma: current treatment and future challenges. Nat
Rev Clin Oncol. 7:163–172. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Aparicio JR, Martínez J, Niveiro M, et al:
Direct intracystic biopsy and pancreatic cystoscopy through a
19-gauge needle EUS (with videos). Gastrointest Endosc.
72:1285–1288. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Falco A, Rosati A, Festa M, et al: BAG3 is
a novel serum biomarker for pancreatic adenocarcinomas. Am J
Gastroenterol. 108:1178–1180. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kosanam H, Prassas I, Chrystoja CC, et al:
Laminin, gamma 2 (LAMC2): a promising new putative pancreatic
cancer biomarker identified by proteomic analysis of pancreatic
adenocarcinoma tissues. Mol Cell Proteomics. 12:2820–2832. 2013.
View Article : Google Scholar
|
|
6
|
Wang Y, Kuramitsu Y, Ueno T, et al:
Proteomic differential display identifies upregulated vinculin as a
possible biomarker of pancreatic cancer. Oncol Rep. 28:1845–1850.
2012.PubMed/NCBI
|
|
7
|
Wang T, Wentz SC, Ausborn NL, et al:
Pattern of breast cancer susceptibility gene 1 expression is a
potential prognostic biomarker in resectable pancreatic ductal
adenocarcinoma. Pancreas. 42:977–982. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tempero MA, Klimstra D, Berlin J, et al:
Changing the way we do business: recommendations to accelerate
biomarker development in pancreatic cancer. Clin Cancer Res.
19:538–540. 2013. View Article : Google Scholar
|
|
9
|
Ray P, Sullenger BA and White RR: Further
characterization of the target of a potential aptamer biomarker for
pancreatic cancer: cyclophilin B and its posttranslational
modifications. Nucleic Acid Ther. 23:435–442. 2013. View Article : Google Scholar
|
|
10
|
Ray P, Rialon-Guevara KL, Veras E,
Sullenger BA and White RR: Comparing human pancreatic cell
secretomes by in vitro aptamer selection identifies cyclophilin B
as a candidate pancreatic cancer biomarker. J Clin Invest.
122:1734–1741. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ono M, Kamita M, Murakoshi Y, et al:
Biomarker discovery of pancreatic and gastrointestinal cancer by
2DICAL: 2-dimensional image-converted analysis of liquid
chromatography and mass spectrometry. Int J Proteomics.
2012:8974122012.PubMed/NCBI
|
|
12
|
Lyn-Cook BD, Yan-Sanders Y, Moore S,
Taylor S, Word B and Hammons GJ: Increased levels of NAD(P)H:
quinone oxidoreductase 1 (NQO1) in pancreatic tissues from smokers
and pancreatic adenocarcinomas: A potential biomarker of early
damage in the pancreas. Cell Biol Toxicol. 22:73–80. 2006.
View Article : Google Scholar
|
|
13
|
Lau C, Kim Y, Chia D, et al: Role of
pancreatic cancer-derived exosomes in salivary biomarker
development. J Biol Chem. 288:26888–26897. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hahne M, Kataoka T, Schröter M, et al:
APRIL, a new ligand of the tumor necrosis factor family, stimulates
tumor cell growth. J Exp Med. 188:1185–1190. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chuang MJ, Sun KH, Tang SJ, Deng MW, Wu
YH, Sung JS, Cha TL and Sun GH: Tumor-derived tumor necrosis
factor-alpha promotes progression and epithelial-mesenchymal
transition in renal cell carcinoma cells. Cancer Sci. 99:905–913.
2008. View Article : Google Scholar
|
|
16
|
Takahashi E, Nagano O, Ishimoto T, Yae T,
Suzuki Y, Shinoda T, Nakamura S, Niwa S, Ikeda S and Koga H: Tumor
necrosis factor-α regulates transforming growth factor-β-dependent
epithelial-mesenchymal transition by promoting
hyaluronan-CD44-moesin interaction. J Biol Chem. 285:4060–4073.
2010.
|
|
17
|
Dillon SR, Harder B, Lewis KB, et al:
B-lymphocyte stimulator/a proliferation-inducing ligand
heterotrimers are elevated in the sera of patients with autoimmune
disease and are neutralized by atacicept and B-cell maturation
antigen-immunoglobulin. Arthritis Res Ther. 12:R482010. View Article : Google Scholar
|
|
18
|
Xin G, Cui Z, Su Y, Xu LX, Zhao MH and Li
KS: Serum BAFF and APRIL might be associated with disease activity
and kidney damage in patients with anti-glomerular basement
membrane disease. Nephrology (Carlton). 18:209–214. 2013.
View Article : Google Scholar
|
|
19
|
Pollard RP, Abdulahad WH, Vissink A, et
al: Serum levels of BAFF, but not APRIL, are increased after
rituximab treatment in patients with primary Sjogren’s syndrome:
data from a placebo-controlled clinical trial. Ann Rheum Dis.
72:146–148. 2013.
|
|
20
|
Gheita TA, Raafat H, Khalil H and Hussein
H: Serum level of APRIL/BLyS in Behcet’s disease patients: clinical
significance in uveitis and disease activity. Mod Rheumatol.
23:542–546. 2013.PubMed/NCBI
|
|
21
|
Kiyama K, Kawabata D, Hosono Y, et al:
Serum BAFF and APRIL levels in patients with IgG4-related disease
and their clinical significance. Arthritis Res Ther. 14:R862012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang F, Chen L, Ding W, et al: Serum
APRIL, a potential tumor marker in pancreatic cancer. Clin Chem Lab
Med. 49:1715–1719. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tecchio C, Nichele I, Mosna F, et al: A
proliferation-inducing ligand (APRIL) serum levels predict time to
first treatment in patients affected by B-cell chronic lymphocytic
leukemia. Eur J Haematol. 87:228–234. 2011. View Article : Google Scholar
|
|
24
|
Ding W, Wang J, Wang F, et al: Serum
sAPRIL: a potential tumor-associated biomarker to colorectal
cancer. Clin Biochem. 46:1590–1594. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM Classification of Malignant Tumours. 28. 7th edition.
Wiley-Blackwell; West Sussex, UK: pp. 231–234. 2009
|
|
26
|
Takano S, Yoshitomi H, Togawa A, et al:
Apolipoprotein C-1 maintains cell survival by preventing from
apoptosis in pancreatic cancer cells. Oncogene. 27:2810–2822. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Blumenstein B, Saad F, Hotte S, et al:
Reduction in serum clusterin is a potential therapeutic biomarker
in patients with castration-resistant prostate cancer treated with
custirsen. Cancer Med. 2:468–477. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu Y, Du X, Xue C, et al: Quantification
of serum SOX2 DNA with FQ-PCR potentially provides a diagnostic
biomarker for lung cancer. Med Oncol. 30:7372013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Harima Y, Ikeda K, Utsunomiya K, et al:
Apolipoprotein C-II is a potential serum biomarker as a prognostic
factor of locally advanced cervical cancer after chemoradiation
therapy. Int J Radiat Oncol Biol Phys. 87:1155–1161. 2013.
View Article : Google Scholar
|
|
30
|
Toiyama Y, Hur K, Tanaka K, et al: Serum
miR-200c is a novel prognostic and metastasis-predictive biomarker
in patients with colorectal cancer. Ann Surg. 259:735–743. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang J, Wang X, Lin S, et al:
Identification of kininogen-1 as a serum biomarker for the early
detection of advanced colorectal adenoma and colorectal cancer.
PLoS One. 8:e705192013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Biskup K, Braicu EI, Sehouli J, et al:
Serum glycome profiling: a biomarker for diagnosis of ovarian
cancer. J Proteome Res. 12:4056–4063. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu R, Chen X, Du Y, et al: Serum microRNA
expression profile as a biomarker in the diagnosis and prognosis of
pancreatic cancer. Clin Chem. 58:610–618. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Eguchi H, Ishikawa O, Ohigashi H, et al:
Serum REG4 level is a predictive biomarker for the response to
preoperative chemoradiotherapy in patients with pancreatic cancer.
Pancreas. 38:791–798. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dutta SK, Girotra M, Singla M, et al:
Serum HSP70: a novel biomarker for early detection of pancreatic
cancer. Pancreas. 41:530–534. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Brand RE, Nolen BM, Zeh HJ, et al: Serum
biomarker panels for the detection of pancreatic cancer. Clin
Cancer Res. 17:805–816. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Boeck S, Wittwer C, Heinemann V, et al:
Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker
for response and survival in patients with advanced pancreatic
cancer. Br J Cancer. 108:1684–1694. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen X, Ba Y, Ma L, et al:
Characterization of microRNAs in serum: a novel class of biomarkers
for diagnosis of cancer and other diseases. Cell Res. 18:997–1006.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sugiura T, Uesaka K, Mihara K, et al:
Margin status, recurrence pattern, and prognosis after resection of
pancreatic cancer. Surgery. 154:1078–1086. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kitamura K, Seike M, Okano T, et al:
MiR-134/487b/655 cluster regulates TGF-β-induced
epithelial-mesenchymal transition and drug resistance to gefitinib
by targeting MAGI2 in lung adenocarcinoma cells. Mol Cancer Ther.
13:444–453. 2014.PubMed/NCBI
|
|
41
|
Mackay F and Ambrose C: The TNF family
members BAFF and APRIL: the growing complexity. Cytokine Growth
Factor Rev. 14:311–324. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lascano V, Zabalegui LF, Cameron K, et al:
The TNF family member APRIL promotes colorectal tumorigenesis. Cell
Death Differ. 19:1826–1835. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Watanabe T, Takahashi A, Suzuki K, et al:
Epithelial-mesenchymal transition in human gastric cancer cell
lines induced by TNF-α-inducing protein of Helicobacter
pylori. Int J Cancer. 134:2373–2382. 2014.
|
|
44
|
Wang H, Fang R, Wang XF, et al:
Stabilization of Snail through AKT/GSK-3β signaling pathway is
required for TNF-α-induced epithelial-mesenchymal transition in
prostate cancer PC3 cells. Eur J Pharmacol. 714:48–55.
2013.PubMed/NCBI
|
|
45
|
Wang H, Wang HS, Zhou BH, et al:
Epithelial-mesenchymal transition (EMT) induced by TNF-α requires
AKT/GSK-3β-mediated stabilization of snail in colorectal cancer.
PLoS One. 8:e566642013.
|
|
46
|
Techasen A, Namwat N, Loilome W, et al:
Tumor necrosis factor-α (TNF-α) stimulates the
epithelial-mesenchymal transition regulator Snail in
cholangiocarcinoma. Med Oncol. 29:3083–3091. 2012.
|
